The Predictive Value of the Prognostic StagingSystem in the 8th Edition of the American Joint Committee on Cancer for Triple-Negative Breast Cancer: A SEER Population-Based Analysis

References

• Gluz O , LiedtkeC, GottschalkN, PusztaiL, NitzU, HarbeckN. Triple-negative breast cancer – current status and future directions. Ann. Oncol.20(12), 1913–1927 (2009).
   PubMed Web of Science ®Google Scholar
• Dent R , TrudeauM, PritchardKIet al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res.13(15 Pt 1), 4429–4434 (2007).
   PubMed Web of Science ®Google Scholar
• Dent R , HannaWM, TrudeauM, RawlinsonE, SunP, NarodSA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat.115(2), 423–428 (2009).
   PubMed Web of Science ®Google Scholar
• Chu QD , TariK, ThelmaH. Triple-negative breast cancer. N. Engl. J. Med.363(20), 1938–1948 (2010).
   PubMed Web of Science ®Google Scholar
• Denkert C , LiedtkeC, TuttA, Von MinckwitzG. Molecular alterations in triple-negative breast cancer – the road to new treatment strategies. Lancet389(10087), 2430–2442 (2017).
   PubMed Web of Science ®Google Scholar
• Plichta JK , CampbellBM, MittendorfEA, HwangES. Anatomy and breast cancer staging: is it still relevant?Surg. Oncol. Clin. N. Am.27(1), 51–67 (2018).
   PubMed Web of Science ®Google Scholar
• Park YH , LeeSJ, ChoEYet al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann. Oncol.22(7), 1554–1560 (2011).
   PubMed Web of Science ®Google Scholar
• Bagaria SP , RayPS, SimMSet al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg.149(2), 125–129 (2014).
   PubMed Web of Science ®Google Scholar
• Orucevic A , ChenJ, McLoughlinJM, HeidelRE, PanellaT, BellJ. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer – an institution’s 10-year experience. Breast J.21(2), 147–154 (2015).
   PubMed Web of Science ®Google Scholar
• Amin MB , GreeneFL, EdgeSBet al. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin.67(2), 93–99 (2017).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O . Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res. Treat.168(1), 269–275 (2018).
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O . Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis. Breast Cancer Res. Treat.164(1), 231–236 (2017).
   PubMed Web of Science ®Google Scholar
• Wang M , ChenH, WuK, DingA, ZhangM, ZhangP. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: an analysis based on SEER 18 database. Breast37, 56–63 (2018).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ , AndersonBO, BalassanianRet al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J. Natl Compr. Canc. Netw.15(4), 433 (2017).
   PubMed Web of Science ®Google Scholar
• Burke HB . Outcome prediction and the future of the TNM staging system. J. Natl Cancer Inst.96(19), 1408–1409 (2004).
   PubMedGoogle Scholar
• Barbieri V , SanpaoloP, GenovesiD. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Breast J.17(4), 377–382 (2011).
   PubMed Web of Science ®Google Scholar
• Elnashar AT , Ali ElSM, GaberA. The prognostic value of triple negative in stage II/III breast cancer. J. Oncol. Pharm. Pract.18(1), 68–75 (2012).
   PubMedGoogle Scholar
• Yi M , MittendorfEA, CormierJNet al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J. Clin. Oncol.29(35), 4654–4661 (2011).
   PubMed Web of Science ®Google Scholar
• Soerjomataram I , LouwmanMW, RibotJG, RoukemaJA, CoeberghJW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res. Treat.107(3), 309–330 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartz AM , HensonDE, ChenD, RajamarthandanS. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program. Arch. Pathol. Lab. Med.138(8), 1048–1052 (2014).
   PubMed Web of Science ®Google Scholar
• Yu KD , JiangYZ, HaoS, ShaoZM. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. BMC Med.13, 254 (2015).
   PubMed Web of Science ®Google Scholar
• Ahmed SS , ThikeAA, ZhangK, LimJC, TanPH. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. J. Clin. Pathol.70(4), 320–326 (2017).
   PubMed Web of Science ®Google Scholar
• Chan M , ChangMC, GonzalezRet al. Outcomes of estrogen receptor negative and progesterone receptor positive breast cancer. PLoS ONE10(7), e0132449 (2015).
   PubMed Web of Science ®Google Scholar
• Lee SB , SohnG, KimJet al. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. Breast Cancer Res. Treat.23(8), 1–10 (2018).
   Google Scholar
• Ye J , WangW, XuLet al. A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer. Chin. J. Cancer Res.29(4), 351–360 (2017).
   PubMed Web of Science ®Google Scholar